Visante: Drug Manufacturer Coupons Raise Costs in Medicare Part D, Hurting Vulnerable Beneficiaries
May 11, 2020
The Office of the Inspector General (OIG) of the Department of Health and Human Services (HHS) currently bans manufacturer coupons...
Filter by:
Choose a Topic
Filter by Year:Clear Filters- Research
- Biosimilars
- Drug Abuse Prevention
- Drug Adherence Programs
- Drug Cost Management
- Drug Coupons & Assistance Programs
- Drug Coverage Mandates
- Drug Price Negotiations & Rebates
- Employers, Unions, & Insurers
- FEHB Program
- Formulary Design
- Fraud, Waste, & Abuse
- Generic Drug Utilization
- Health Insurance Marketplace (ACA)
- Home Delivery of Drugs
- Medicaid
- Medicare Part D
- Patient Cost Sharing
- Pharmacy Networks
- Pharmacy Reimbursement & Contracting
- REMS Management
- Specialty Benefit Design
- Specialty Pharmacies
- Specialty Pharmacy Networks
- TRICARE
Visante: Increased Costs Associated With Proposed State Legislation Impacting PBM Tools
April 01, 2020
Visante was commissioned by the Pharmaceutical Care Management Association (PCMA) to estimate the potential cost impact of four types of...
Independent Pharmacies in the U.S. are More on the Rise than on the Decline
March 05, 2020
The independent pharmacy lobby is urging state legislatures to enact new legislation targeting pharmacy benefit managers (PBMs) that would increase...
New Study: Pharmacy Benefit Managers (PBMs): The Return on Investment (ROI) on PBM Services
February 25, 2020
Pharmacy benefit managers (PBMs) save consumers and payers an average of $962 per person, per year, which is a $21...
New Study: Pharmacy Benefit Managers (PBMs): Generating Savings for Plan Sponsors and Consumers
February 19, 2020
Pharmacy Benefit Managers (PBMs) now implement prescription drug benefits for some 266 million Americans who have health insurance from a...
Rebuttal of USC Schaeffer’s “The Association Between Drug Rebates and List Prices”
February 15, 2020
A recent white paper (“The Association Between Drug Rebates and List Prices”) narrowly suggests an association between list prices for brand...
Pennsylvania Medicaid MCO Prescription Drug Repricing: Cost Impacts of Using NADAC Payment Structure
November 14, 2019
Pennsylvania has proposed legislation (PA HB 941) to reconfigure the payment rates used for Medicaid prescriptions paid by Medicaid MCOs...
October 31, 2019
Most state Medicaid programs have predominantly transitioned the prescription drug benefit to the managed care setting, through which Medicaid managed...
July 11, 2019
A recent report from the Massachusetts Health Policy Commission used publicly available drug pricing data in an attempt to identify...
May 10, 2019
Recent reports from 46brooklyn Research and their consulting arm 3 Axis Advisors have used publicly available drug pricing data, and...
March 18, 2019
Senior voters with Part D plans have largely not heard about proposed changes to Part D, however, and will punish...
February 26, 2019
Increasing Drug List Prices Show No Correlation with Change in Rebates (2012–2017) View the Infographic Major Findings: Increasing list prices...